Clinical Trials
24 trialsNCT03386500 2026-05-18
Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer
University of Nebraska
Phase 1/2 Active not recruiting
NCT04432597 2026-05-18
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT03233711 2026-05-13
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04929028 2026-05-13
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02314169 2026-05-12
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04166318 2026-05-05
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT04444921 2026-05-04
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04287868 2026-04-13
Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT05858736 2026-04-09
PRESERVE-009
OncoC4, Inc.
Phase 1 Active not recruiting
NCT04708470 2026-04-06
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT04141449 2025-12-31
Potlako+
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT05902533 2025-12-18
REDEL
University of Cincinnati
Phase 2/3 Active not recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT04046133 2025-08-05
CORINTH
Cardiff University
Phase 1 Active not recruiting
NCT06866574 2025-07-31
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University
Phase 3 Active not recruiting
NCT02816879 2025-07-29
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men
Jonsson Comprehensive Cancer Center
Phase NA Active not recruiting
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT04719988 2024-12-20
INTERACT-ION
Centre Hospitalier Universitaire de Besancon
Phase 2 Active not recruiting
NCT06465914 2024-12-12
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Active not recruiting
NCT03018418 2024-09-19
Proton Therapy in Reducing Toxicity in Anal Cancer
University of Cincinnati
Phase 2 Active not recruiting
NCT04230759 2024-09-19
RADIANCE
Goethe University
Phase 2 Active not recruiting
NCT05385250 2024-08-15
DACG-II
Aarhus University Hospital
Phase NA Active not recruiting
NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting